Albireo Announces Proposed Public Offering of Common Stock

BOSTON, May 23, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an … [Read more...]

argenx announces closing of NASDAQ IPO

Regulated information Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the "Offering") of 6,744,750 American Depositary Shares ("ADSs"), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. This includes the full … [Read more...]

Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)

SB 9200 Shows Favorable Safety Profile and Significant Antiviral Activity Against HBV DNA and HBsAg with Initial Low Dose Monotherapy of 25mg Conference Call Scheduled for Tomorrow, May 24th at 8:00 a.m. ET HOPKINTON, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today the top-line results from the 25mg … [Read more...]

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research. … [Read more...]